Patent covers a virus-like particle comprising a viral structural protein comprising modified envelope protein E3

Gaithersburg, Md. — May 18, 2018 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and new cancer therapies, announced that the U.S. Patent and Trademark Office has issued US Patent #9,969,986 covering a virus like particle comprising modified envelope protein E3. The patent protects key composition of matter of VLP’s proprietary i-αVLP virus-like particle platform technology and the pharmaceutical composition for use in preventing infectious disease and the treatment of cancer. VLP Therapeutics is currently focused on developing preventative infectious disease vaccines and therapeutic cancer vaccines utilizing the platform technology covered by patent #9,969,986 and other issued US patents,

“We are delighted to have achieved this milestone which provides strong protection for our new platform technology using alphavirus VLP. We strongly believe that this technology represents next generation vaccine platform targeting to broad indications such as cancer and infectious disease.” said Chief Executive Officer, Dr. Wataru Akahata. “Our lead vaccine candidate, VLPM01 malaria vaccine, will enter a Phase I/IIa clinical trial in 2018.  Based on this new invention, more people can benefit for many indications,” he continued.

About VLP Therapeutics

VLP Therapeutics is developing next-generation vaccines and therapies to fight infectious diseases and cancer. Through our patent-protected virus modification capabilities we can deliver antigens on the exterior and genetic material on the interior of viruses in a highly immunogenic and efficient manner. We have created highly versatile virus-like particle (VLP) platforms which harness a virus’s innate ability to infiltrate the human body while disabling the virus’s ability to replicate. We are developing novel therapies that address significant unmet medical needs and will reach countless patients around the world. VLP vaccines have a record of safety, efficacy and commercial success, having successfully been marketed to prevent human papilloma virus and hepatitis B. VLP Therapeutics is located in Gaithersburg, MD.

About i-α VLP Technology

The human immune system is biologically designed to protect us against disease. The immune system detects foreign objects such as viruses, bacteria or abnormal self-tissues (like cancer cells) in the body, and not only tries to eliminate these foreign objects, but also “memorizes” them so it can protect the body from them in the future. Vaccines utilize the immune system to protect us from various diseases.
Unlike traditional vaccines, are which are made using live viruses, VLP’s novel, proprietary platform technology utilizes virus-like particles. Virus-like particles are identical to the authentic native viruses in their shapes, but do not carry the genetic material of native viruses. Without the genetic material, these particles cannot replicate themselves. This means that when the virus-like particles are presented within our bodies, our immune system will recognize the particles as foreign objects, triggering effective immune responses, but should not cause the risk of side effects associated with the native virus due to the absence of genetic material.

Utilizing these virus-like particles, VLP Therapeutics has developed a proprietary, “plug-and-play” platform called inserted alphavirus virus-like particle (i-αVLP) using the Chikungunya virus (CHIKV) VLP. Through this adaptable platform, foreign antigens can be inserted into two specific sites of the envelope protein on the surface of i-αVLP. With 240 copies of envelope protein per CHIKV VLP, each i-αVLP can display a tremendous 480 copies of an inserted antigen. This highly symmetrical, icosahedral dense array of antigens has been shown in our studies to induce very strong immune responses, resulting in its superior efficacy. VLP Therapeutics has established a method to efficiently produce i-αVLPs which it believes can be scaled for commercial production.


Wataru Akahata, CEO

Jacob Licht, COO